{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:45:11Z","timestamp":1782978311378,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Austrian Science promotion agency","award":["845557"],"award-info":[{"award-number":["845557"]}]},{"name":"Austrian Science promotion agency","award":["851517"],"award-info":[{"award-number":["851517"]}]},{"name":"Austrian Science promotion agency","award":["857707"],"award-info":[{"award-number":["857707"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.nbd.2020.104943","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:46:16Z","timestamp":1589233576000},"page":"104943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease"],"prefix":"10.1016","volume":"141","author":[{"given":"Stefan","family":"Bartl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Oueslati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Southwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Siddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Parth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Suzanne","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Maxan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Salhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Burkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mairhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halyna","family":"Pankevych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Balazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Staffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar W.","family":"Smrzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2020.104943_bb0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1515\/bmc-2015-0001","article-title":"The emerging role of the first 17 amino acids of huntingtin in Huntington\u2019s disease","volume":"6","author":"Arndt","year":"2015","journal-title":"Biomol Concepts"},{"key":"10.1016\/j.nbd.2020.104943_bb0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2020.104943_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.07.032","article-title":"mHTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington\u2019s disease","volume":"71","author":"Ast","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.nbd.2020.104943_bb0020","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","article-title":"Weight loss in Huntington disease increases with higher CAG repeat number","volume":"71","author":"Aziz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2020.104943_bb0025","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1468-1331.2008.02173.x","article-title":"Cardiovagal modulation upon postural change is altered in Huntington\u2019s disease","volume":"15","author":"Bar","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2020.104943_bb0030","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","article-title":"Huntingtin aggregation and toxicity in Huntington\u2019s disease","volume":"361","author":"Bates","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2020.104943_bb0035","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.nbd.2020.104943_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.104943_bb0045","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1073\/pnas.1301342110","article-title":"Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin","volume":"110","author":"Caron","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.104943_bb0050","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","article-title":"Treating the whole body in Huntington\u2019s disease","volume":"14","author":"Carroll","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2020.104943_bb0055","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1073\/pnas.0904239106","article-title":"Neural transplants in patients with Huntington\u2019s disease undergo disease-like neuronal degeneration","volume":"106","author":"Cicchetti","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.104943_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","article-title":"Mutant huntingtin is present in neuronal grafts in Huntington disease patients","volume":"76","author":"Cicchetti","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2020.104943_bb0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/hyb.2005.24.231","article-title":"Epitope mapping of monoclonal antibody 4C8 recognizing the protein huntingtin","volume":"24","author":"Cong","year":"2005","journal-title":"Hybridoma (Larchmt)"},{"key":"10.1016\/j.nbd.2020.104943_bb0070","first-page":"3678","article-title":"Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes","volume":"126","author":"Costanzo","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.nbd.2020.104943_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","article-title":"Tau passive immunization inhibits not only tau but also Abeta pathology","volume":"9","author":"Dai","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2020.104943_bb0080","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.jmb.2015.03.021","article-title":"Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression","volume":"427","author":"De Genst","year":"2015","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2020.104943_bb0085","doi-asserted-by":"crossref","first-page":"18540","DOI":"10.1074\/jbc.RA118.004621","article-title":"N-terminal huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting","volume":"293","author":"DeGuire","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.104943_bb0090","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","article-title":"Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation","volume":"34","author":"El-Daher","year":"2015","journal-title":"EMBO J."},{"key":"10.1016\/j.nbd.2020.104943_bb0095","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease Minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2020.104943_bb0100","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/hmg\/7.9.1463","article-title":"Huntingtin interacts with a family of WW domain proteins","volume":"7","author":"Faber","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.104943_bb0105","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1523\/JNEUROSCI.6379-11.2012","article-title":"Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment","volume":"32","author":"Gafni","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JPD-150630","article-title":"Immunotherapy in Parkinson\u2019s disease: micromanaging alpha-Synuclein aggregation","volume":"5","author":"George","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2020.104943_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0891-0618(00)00073-9","article-title":"Stereology, morphometry, and mapping: the whole is greater than the sum of its parts","volume":"20","author":"Glaser","year":"2000","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.nbd.2020.104943_bb0120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng0896-442","article-title":"Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract","volume":"13","author":"Goldberg","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.nbd.2020.104943_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature25502","article-title":"The cryo-electron microscopy structure of huntingtin","volume":"555","author":"Guo","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.nbd.2020.104943_bb0130","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0135","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1083\/jcb.141.5.1097","article-title":"The influence of huntingtin protein size on nuclear localization and cellular toxicity","volume":"141","author":"Hackam","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.nbd.2020.104943_bb0140","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2020.104943_bb0145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14712590902828285","article-title":"Is passive immunization for Alzheimer\u2019s disease \u2018alive and well\u2019 or \u2018dead and buried\u2019?","volume":"9","author":"Jicha","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2020.104943_bb0150","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","article-title":"Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity","volume":"99","author":"Khoshnan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.104943_bb0155","doi-asserted-by":"crossref","first-page":"12784","DOI":"10.1073\/pnas.221451398","article-title":"Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington\u2019s disease brains, associate with membranes, and undergo calpain-dependent proteolysis","volume":"98","author":"Kim","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.104943_bb0160","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron."},{"key":"10.1016\/j.nbd.2020.104943_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","article-title":"Bone marrow transplantation confers modest benefits in mouse models of Huntington\u2019s disease","volume":"32","author":"Kwan","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archneur.65.4.476","article-title":"Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion","volume":"65","author":"Lalic","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2020.104943_bb0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/978-1-4939-7825-0_23","article-title":"Translating antisense technology into a treatment for Huntington\u2019s disease","volume":"1780","author":"Lane","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2020.104943_bb0180","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1471-4159.2007.05064.x","article-title":"Antibody-based approaches in Alzheimer\u2019s research: safety, pharmacokinetics, metabolism, and analytical tools","volume":"104","author":"Lichtlen","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.104943_bb0185","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jasms.2007.04.012","article-title":"Mapping the human plasma proteome by SCX-LC-IMS-MS","volume":"18","author":"Liu","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.nbd.2020.104943_bb0190","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/hmg\/ddu574","article-title":"Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington\u2019s disease","volume":"24","author":"Liu","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.104943_bb0195","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fnins.2017.00647","article-title":"The evidence for the spread and seeding capacities of the mutant huntingtin protein in in vitro systems and their therapeutic implications","volume":"11","author":"Masnata","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0200","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00401-019-01973-6","article-title":"Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms","volume":"137","author":"Masnata","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2020.104943_bb0205","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2020.104943_bb0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuron.2010.06.021","article-title":"Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington\u2019s disease","volume":"67","author":"Miller","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2020.104943_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and Lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.nbd.2020.104943_bb0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/nan.12264","article-title":"Hunting cellular mechanisms underlying the spreading of misfolded protein pathology in the brain","volume":"42","author":"Pecho-Vrieseling","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.nbd.2020.104943_bb0225","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1016\/j.bpj.2012.04.050","article-title":"Fibrillar alpha-synuclein and huntingtin exon 1 assemblies are toxic to the cells","volume":"102","author":"Pieri","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.nbd.2020.104943_bb0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1523\/JNEUROSCI.1409-03.2004","article-title":"Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction","volume":"24","author":"Qin","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0235","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington\u2019s disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.nbd.2020.104943_bb0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncb1830","article-title":"Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates","volume":"11","author":"Ren","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.nbd.2020.104943_bb0245","doi-asserted-by":"crossref","first-page":"852","DOI":"10.4161\/hv.28578","article-title":"Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?","volume":"10","author":"Romero-Ramos","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.nbd.2020.104943_bb0250","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.nbd.2020.104943_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155747","article-title":"Folding landscape of mutant huntingtin Exon1: diffusible multimers, oligomers and fibrils, and no detectable monomer","volume":"11","author":"Sahoo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.104943_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23051068","article-title":"Passive Abeta immunotherapy: current achievements and future perspectives","volume":"23","author":"Schilling","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.nbd.2020.104943_bb0265","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2020.104943_bb0270","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0275","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2020.104943_bb0285","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2020.104943_bb0290","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0b013e318282514e","article-title":"Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease","volume":"80","author":"Stuwe","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2020.104943_bb0295","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fnins.2018.00254","article-title":"Antibody engineering for optimized immunotherapy in Alzheimer\u2019s disease","volume":"12","author":"Sumner","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2020.104943_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/cells7060059","article-title":"Unconventional secretion and intercellular transfer of mutant huntingtin","volume":"7","author":"Tang","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.nbd.2020.104943_bb0305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/nmt.12.34","article-title":"Monitoring Huntington's disease progression through preclinical and early stages","volume":"2","author":"Tang","year":"2012","journal-title":"Neurodegener. Dis. Manag."},{"issue":"Suppl. 1","key":"10.1016\/j.nbd.2020.104943_bb0310","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jnc.13529","article-title":"Therapeutic approaches in Parkinson\u2019s disease and related disorders","volume":"139","author":"Valera","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.104943_bb0315","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nm.3569","article-title":"Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice","volume":"20","author":"Villeda","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2020.104943_bb0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-007-0306-6","article-title":"Huntington disease models and human neuropathology: similarities and differences","volume":"115","author":"Vonsattel","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2020.104943_bb0325","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","article-title":"Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease","volume":"17","author":"Wang","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.104943_bb0330","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2020.104943_bb0335","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","article-title":"Immunotherapeutic approaches for Alzheimer\u2019s disease","volume":"85","author":"Wisniewski","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2020.104943_bb0340","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","article-title":"Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells","volume":"11","author":"Yang","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.104943_bb0345","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-12-385883-2.00010-2","article-title":"Huntington disease and the huntingtin protein","volume":"107","author":"Zheng","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.nbd.2020.104943_bb0350","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in Huntington\u2019s disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front. Physiol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120302187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120302187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:20:47Z","timestamp":1760851247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996120302187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":70,"alternative-id":["S0969996120302187"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2020.104943","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2020.104943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104943"}}